Antituberculous agents–induced liver injury

Drug-Induced Liver Disease

Volumn , Issue , 2002, Pages 505-518

  Garg, Pramod Kumar ^a   Tandon, Rakesh Kumar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056683021     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (70)

1. Reider HL. Misbehavior of a dying epidemic: a call for less speculation and better surveillance (editorial). Tuberc Lung Dis 1992; 73:181-182.
2. Snider DE, Jr., Cohn DL, Davidson PT, et al. Standard therapy for tuberculosis. Chest 1985; 87(suppl):117S-124S.
3. Mahashur AA, Prabhudesai PP. Hepatitis and antitubercular therapy. J Assoc Physicians India 1991; 39:595-596.
4. Gangadharam PR. Isoniazid, rifampin and hepatotoxicity (editorial). Am Rev Respir Dis 1986; 133:963-965.
5. Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid associated deaths in one state. Am Rev Respir Dis 1989; 140:700-705.
6. Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969; 71:113-120.
7. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid associated hepatitis: report of an outbreak. Am Rev Respir Dis 1972; 106:357-365.
8. Kopanoff DE, Sinder DE, Caras GH. Isoniazid-related hepatitis A. U.S. Public Health Service Cooperative Surveillance Study. Am Rev Respir Dis 1978; 117:991-1001.
9. Brummer DL. Isoniazid and liver disease. Ann Intern Med 1971; 75:643.
10. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281:1014-1018.
11. Cohen R, Kalser MH, Thomson RV. Fatal hepatic necrosis secondary to isoniazid therapy. JAMA 1961; 176:877-879.
12. Snider DE, Caras GH. Isoniazid associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145:494-497.
13. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69:289-302.
14. Meddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med 1973; 70:1-12.
15. Mitchell JR, Thorgeirsson UP, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relation to hydrazine metabolites. Clin Pharmacol Ther 1975; 18: 70-79.
16. Mitchell JR, Long MW, Thorgeirsson UP, Jollow DJ. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 1975; 68:181-190.
17. Madell GL, Sande MA. Drugs used in the chemotherapy of tuberculosis and leprosy. In: AS Gilman, LS Goodman, TW Rall, et al., eds. The Pharmacological Basis of Therapeutics. 7th ed. New York: Macmillan Publishing Co., 1985:199-218.
18. Alford RH. Antimycobacterial agents. In: GL Mandell, RJ Douglas, JE Benett, eds. Principles and Practice of Infectious Diseases. 3rd ed. New York: Churchill Livingstone, 1990:350-361.
19. Thompson JE. The effect of rifampicin on liver morphology in tuberculous alcoholics. Aust NZ J Med 1976; 6:111-116.
20. Lees AW, Allan GW, Smith J. Toxicity from rifampin plus isoniazid and rifampicin plus ethambutal therapy. Tubercle 1971; 52:182-190.
21. Releigh JW. Rifampin in treatment of advanced pulmonary tuberculosis. Am Rev Respir Dis 1973; 105:397-409.
22. Hong Kong Tuberculosis Treatment Service/Brompton Hospital/British Medical Research Council. A controlled trial of daily and intermittent rifampicin plus ethambutol in the treatment of patients with pulmonary tuberculosis: results up to 30 months. Tubercle 1975; 56: 79-89.
23. Steele MA, Burk RF, Desprez RM. Toxic hepatitis with isoniazid and rifampicin—a metaanalysis. Chest 1991; 99:465-471.
24. Gupta PR, Purohit JD, Mehta YR, Jain BI, Kotwal S, Sharma TN. Serum and urinary rifampicin and hepatic toxicity. Indian J Tuberc 1985; 32:86-90.
25. Mulder De Jong, Mulder RJ. Drugs used in the treatment of tuberculosis and leprosy. In: MUG Dukes, ed. Meyler’s Side Effects of Drugs. Vol. 1. Oxford: Excerpta Medica, 1977:676-689.
26. Kenwright S, Levi AJ. Sites for competition in selective hepatic uptake of rifampicin SV, flavaspidic acid, billirubin and bromsalphalein. GU 1974; 15:220-226.
27. Girling DJ. The hepatic toxicity of antituberculous regimens containing isoniazid, rifampicin, and pyrazinamide. Tubercle 1978; 59:13-32.
28. Parthasarathy R, Sarma GR, Janardhanam B, et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short course regimens containing isoniazid, rifampin and pyrazinamide. Tubercle 1986; 67:99-108.
29. Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK. Antituberculosis treatment induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995; 71:359-362.
30. Mitchell I, Williams R. Liver transplantation for antituberculous drug induced acute liver failure. Lancet 1995; 345:555.
31. Lal S, Singhal SN, Burley DM, Crossley G. Effect of rifampicin and isoniazid on liver function. Br Med J 1972; 1:148-150.
32. Snider DE, Long MW, Cross PS, Farer LS. Six months isoniazid-rifampin therapy for pulmonary tuberculosis: report of a United States Health Service Cooperative Trial. Am Rev Respir Dis 1984; 129:573-579.
33. Tsagaropoulon-Stinga H, Mataki-Emmanouili T, Karida-Ka-Valioti S, Manios S. Hepatotoxic reactions in children with severe tuberculosis treated with isoniazid-rifampin. Pediatr Infect Dis 1985; 4:270-273.
34. Pessayre D, Bentata M, Degott C, Nonel O, Miguet JP, Rueff B, et al. Isoniazid-rifampin fulminant hepatitis: a possible consequence of the enhancement of isoniazid hepatotoxicity in enzyme induction. Gastroenterology 1977; 72:284-289.
35. Ellard GA, Mitchison DA, Girling DJ, Nunn AJ, Fox W. The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug. Am Rev Respir Dis 1978; 118:628-629.
36. Lauterburg BH, Smith CV, Todd EL, Mitchell JR. Pharmacokinetics of the toxic hydrazine metabolites formed from isoniazid in humans. Pharmacol Exp Ther 1985; 235:566-570.
37. Ellard GA, Gammon PT. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 1976; 4:83-113.
38. Sarma GR, Immanuel C, Naryana ASL, Ventakaterin P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986; 133:1072-1705.
39. Bevve IW, Blair IA, Brodie MJ. Circulating hydrazine during treatment with isoniazid rifampicin in man. Br J Clin Pharmacol 1982; 13:599.
40. Dickinson DS, Bailey WC, Hirschowitz BI. The effect of acetylation status on isoniazid (INH) hepatitis. Am Rev Respir Dis 1977; 115:395.
41. Wiber WW, Hein DW, Litwun A, Lower GM, Jr. Relationship of acetylator status to isoniazid toxicity, lupus erythematosus and bladder cancer. Feb Proc 1983; 42:3086-3090.
42. Sarich TC, Adams SP, Petricca G, Wright JM. Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J Pharmacol Exp Ther 1999; 289:695-702.
43. Gurumurty P, Krishnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984; 129:58-61.
44. Singh J, Garg PK, Thakur VS, Tandon RK. Antitubercular treatment induced hepatotoxicity: does acetylator status matter? Indian J Physiol Pharmacol 1995; 35:43-46.
45. Ohno M, Yamaguchi I, Yamamoto I, et al. Slow V-acetyltransferase 2 genotype affects the incidence of isoniazid-and-rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000; 4:256-261.
46. Centers for Disease Control. National Consensus Conference on Tuberculosis. Preventive Treatment of Tuberculosis. Chest 1985; 87(suppl 2):128-132.
47. Teneja DP, Dalip K. Study of hepatotoxicity and other side effects of antitubercular drugs. J Indian Med Assoc 1990; 88:278-279.
48. van den Brande P, van Steenbergen W, Vervoort G, Demedts M. Aging and hepatotoxicity of isoniazid and rifampicin in pulmonary tuberculosis. Am J Respir Crit Care Med 1995; 152(5 Pt 1):1705-1708.
49. Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculous treatment: an 11-year study. Tuberc Lung Dis 1996; 77:335-340.
50. Gronhagen-Riska C, Hellstrom PE, Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118:461-466.
51. Riska N. Hepatitis cases in INH treated groups and in a control group. Bull Int Un Tubercle 1976; 51:203.
52. McGlynn KA, Lustbader ED, Sharma RG, Murphy EC, London WT. Isoniazid prophylaxis in hepatitis B carriers. Am Rev Respir Dis 1986; 134:666-668.
53. Wu JC, Lee SD, Yeh PF, Chan CY, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98:502-504.
54. Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31:201-206.
55. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157(6 Pt 1):1871-1876.
56. Mehta S, Nain CK, Sharma B, Mathur VS. Metabolism of sulfadiazine in children with protein-calorie malnutrition. Pharmacology 1980; 21:369-374.
57. Mehta S, Nian CK, Sharma B, Mathur VS. Disposition of four drugs in malnourished children. Drug-Nutrient Interact 1982; 1:205-212.
58. Buchanan N, Eyberg C, Davis MD. Isoniazid pharmacokinetics in Kwashiorkor. S Afr Med J 1979; 56:299-300.
59. Rugmini PS, Mehta S. Hepatotoxicity of isoniazid and rifampin in children. Indian Pediatr 1984; 21:119-124.
60. Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculous drugs: a case control study. Thorax 1996; 51:132-136.
61. Seth V, Beotra A. Hepatic function in relation to acetylator phenotype in children treated with antitubercular drugs. Indian J Med Res 1989; 89:306-309.
62. O’Brien RJ, Long MV, Floy SC, Lyle MA, Snider DE, Jr. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis. Pediatrics 1983; 72:191-199.
63. Vasudhiphan P, Chiemanya S. Evaluation of rifampin in the treatment of tuberculous meningitis in children. J Pediatr 1975; 87:983.
64. Kumar A, Misra PK, Mehotra R, Govil YC and Rana GS. Hepatotoxicity of rifampin and isoniazid. Is it all drug induced hepatitis? Am Rev Respir Dis 1991; 16:544.
65. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculous therapy: clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996; 22.
66. Turktas H, Unsal M, Tulek N, Oruc O. Hepatotoxicity of antituberculous therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. Tuberc Lung Dis 1994; 75:58-60.
67. Treatment of tuberculosis and tuberculosis infection in adults and children. Position paper of American Thoracic Society 1994 (source-www.thoracic.org).
68. Durand F, Bernuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant and subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995; 21:929-932.
69. Davidson PT, Le HQ. Drug treatment of tuberculosis. Drugs 1992; 43:651-673.
70. Ansari MM, Beg MH, Haleem S. Hepatitis in patients with surgical complications of pulmonary tuberculosis. Indian J Chest Dis Allied Sci 1991; 33:133-138.